DelveInsight's "Traumatic Brain Injury - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Traumatic Brain Injury, historical and forecasted epidemiology as well as the Traumatic Brain Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Traumatic Brain Injury market report provides current treatment practices, emerging drugs, Traumatic Brain Injury market share of the individual therapies, current and forecasted Traumatic Brain Injury market Size from 2018 to 2030 segmented by seven major markets. The Report also covers current Traumatic Brain Injury treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Study Period: 2018-2030
Traumatic brain injury (TBI) is sudden damage to the brain caused by a blow or jolt to the head. Common causes include car or motorcycle crashes, falls, sports injuries, and assaults. Injuries can range from mild concussions to severe permanent brain damage. The injury that occurs at the moment of impact is known as the primary injury.
Primary injuries can involve a specific lobe of the brain or can affect the entire brain. Sometimes the skull may be fractured, but not always. During an accident, the brain crashes back and forth inside the skull causing bruising, bleeding, and tearing of nerve fibers.
Symptoms of a TBI can be mild, moderate, or severe, depending on the extent of the damage to the brain. A mild TBI person may remain conscious or experience a loss of consciousness for a few seconds or minutes. Other symptoms of mild TBI include headache, confusion, lightheadedness, dizziness, blurred vision or tired eyes, ringing in the ears, bad taste in the mouth, fatigue or lethargy, a change in sleep patterns, behavioral or mood changes, and trouble with memory, concentration, attention, or thinking. A person with a moderate or severe TBI may show these same symptoms, but may also have a headache that gets worse or does not go away, repeated vomiting or nausea, convulsions or seizures, an inability to awaken from sleep, dilation of one or both pupils of the eyes, slurred speech, weakness or numbness in the extremities, loss of coordination, and increased confusion, restlessness, or agitation
Approximately half of the severely head-injured patients will need surgery to remove or repair hematomas (ruptured blood vessels) or contusions (bruised brain tissue). Disabilities resulting from a TBI depend upon the severity of the injury, injury’s location, and the individual’s age and general health. Some common disabilities include problems with cognition (thinking, memory, and reasoning), sensory processing (sight, hearing, touch, taste, and smell), communication (expression and understanding), and behavior or mental health (depression, anxiety, personality changes, aggression, acting out, and social inappropriateness).
Traumatic Brain Injury (TBI) Diagnosis and Treatment
It covers the details of conventional and current medical therapies, and diagnosis available in the Traumatic Brain Injury (TBI) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Traumatic Brain Injury (TBI) market report gives a thorough understanding of TBI symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides TBI symptoms of treatment algorithms and treatment guidelines for TBI symptoms in the US, Europe, and Japan.
The epidemiology division’s Traumatic Brain Injury symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Traumatic Brain Injury (TBI) epidemiology segmented as the Total Incident cases of Traumatic Brain Injury (TBI), Severity-specific cases of Traumatic Brain Injury (TBI), Gender-specific cases Traumatic Brain Injury (TBI), Incidence of Traumatic Brain Injury (TBI) by Age Group. The report includes the Incident scenario of TBI symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
The epidemiology segment also provides the Traumatic Brain Injury (TBI) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total 7MM incident cases of Traumatic Brain Injury (TBI) were 4,053,203 in 2020.
The drug chapter segment of the Traumatic Brain Injury (TBI) report encloses the detailed analysis of TBI marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Traumatic Brain Injury (TBI) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Treatment modalities vary extensively based on the severity of the injury and range from daily cognitive therapy sessions to radical surgery such as bilateral decompressed craniotomies. Guidelines have been set forth regarding the optimal TBI management, but they must be taken in the context of the situation and cannot be used in every individual circumstance. Current treatment options for TBI include psychostimulants, antidepressants, antiparkinsonian agents, and anticonvulsants. These agents can manage the neuropsychiatric, neurocognitive, and neurobehavioral sequel of injury to the brain.
Products detail in the report…
Traumatic Brain Injury Emerging Drugs
VAS203 (Ronopterin) is an allosteric iNOS inhibitor and rapidly lowers excessive production of NO resulting from acute iNOS activation. It does not materially affect the physiological production of NO by other constitutive enzymes, which are essential for brain function. By targeting both cerebral blood vessels and cerebral tissue in a region-specific manner, VAS203 represents a completely novel pharmacological approach to TBI that can be administrated in addition to the best standard of care.
Products detail in the report…
The Traumatic Brain Injury market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Traumatic Brain Injury market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Traumatic Brain Injury market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Traumatic Brain Injury market in 7MM is expected to change in the study period 2018-2030.
Key Findings
This section includes a glimpse of the Traumatic Brain Injury (TBI) market in 7MM. The market size of TBI in the seven major markets was USD 6,739 million in 2020 and market is estimated to increase at a CAGR of 5.54% for the study period (2018–2030).
The United States Market Outlook
This section provides a total of Traumatic Brain Injury (TBI) market size and market size by therapies in the United States.
The United States accounts for the largest TBI market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
EU-5 Countries: Market Outlook
The total Traumatic Brain Injury market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Traumatic Brain Injury market size and market size by therapies in Japan is also mentioned.
This section focusses on the rate of uptake of the potential drugs recently launched in the Traumatic Brain Injury market or expected to get launched in the market during the study period 2017-2030. The analysis covers Traumatic Brain Injury market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Traumatic Brain Injury key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Traumatic Brain Injury emerging therapies.
While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to make sure that the patient receives Social Security Disability benefits as quickly as possible and will help the patient avoid the lengthy disability appeal process
To keep up with current market trends, we take KOLs and SME’s opinion working in Traumatic Brain Injury (TBI) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Traumatic Brain Injury (TBI) market trend. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Traumatic Brain Injury Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
1. Key Insights
2. Report Introduction
3. Traumatic Brain Injury Market Overview at a Glance
3.1. Market Share (%) Distribution of Traumatic Brain Injury in 2018
3.2. Market Share (%) Distribution of Traumatic Brain Injury in 2030
4. Executive Summary of Traumatic Brain Injury
5. Disease Background and Overview
5.1. Introduction
5.2. Symptoms
5.3. Etiology
5.4. Pathophysiology
5.4.1. Primary Brain Injuries
5.4.2. Secondary Brain Injuries
5.5. Neurodegenerative conditions associated with TBI
5.6. Diagnosis
5.6.1. CDC Diagnosis Guidelines
5.7. Biomarkers
6. Management and Treatment of TBI
6.1.1. CDC Treatment Guidelines
6.1.2. Guidelines by Brain Trauma Foundation
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. 7MM Total Incident Patient Population of Traumatic Brain Injury
7.3. Epidemiology of Traumatic Brain Injury
7.4. The United States
7.4.1. Incident Cases of Traumatic Brain Injury in the United States
7.4.2. Severity-specific Cases of Traumatic Brain Injury in the United States
7.4.3. Gender-specific Incidence of Traumatic Brain Injury in the United States
7.4.4. Incidence of Traumatic Brain Injury by Age Group in the United States
7.5. EU5
7.5.1. Germany
7.5.2. France
7.5.3. Italy
7.5.4. Spain
7.5.5. United Kingdom
7.6. Japan
7.6.1. Incident Cases of Traumatic Brain Injury in Japan
7.6.2. Severity-specific Cases of Traumatic Brain Injury in Japan
7.6.3. Gender-specific Incidence of Traumatic Brain Injury in Japan
7.6.4. Incidence of Traumatic Brain Injury by Age Group in Japan
8. Organizations contributing to Traumatic Brain Injury
9. Patient Journey
10. Case Reports
11. Emerging Therapies
11.1.VAS203: Vasopharm
11.1.1. Drug Description
11.1.2. Regulatory Milestones
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Product Profile
11.2.NeuroSTAT: NeuroVive Pharmaceutical
11.2.1. Drug Description
11.2.2. Regulatory Milestones
11.2.3. Clinical Development
11.2.4. Clinical Trials Information
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.3.CEVA101: Cellvataion
11.3.1. Drug Description
11.3.2. Regulatory Milestones
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
12. Traumatic Brain Injury: Seven Major Market Analysis
12.1.Key Findings
12.2.Market Size of Traumatic Brain Injury in 7MM
12.3.Market Size of Traumatic Brain Injury by Therapies
12.4.Market Outlook
12.5.United States Market Size
12.5.1. Total Market Size of Traumatic Brain Injury in the United States
12.5.2. Market Size of Traumatic Brain Injury by Therapies in the United States
12.6.EU-5 Market Size
12.6.1. Germany
12.6.2. France
12.6.3. Italy
12.6.4. Spain
12.6.5. United Kingdom
12.7.Japan
12.7.1. Total Market size of Traumatic Brain Injury in Japan
12.7.2. Market Size of Traumatic Brain Injury by Therapies in Japan
13. KOL Views
14. Market Access
15. Market Drivers
16. Market Barriers
17. SWOT Analysis
18. Unmet Needs
19. Appendix
19.1.Bibliography
19.2.Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
List of Tables:
Table 1: Summary of Traumatic Brain Injury, Market, Epidemiology, and Key Events (2018–2030)
Table 2: Criteria for Inclusion and exclusion
Table 3: Four Critical Questions
Table 4: Updated Treatment Recommendations
Table 5: Diagnosed Incident Patient Population of Traumatic Brain Injury in 7MM (2018–2030)
Table 6: Incident Cases of Traumatic Brain Injury in the United States (2018–2030)
Table 7: Severity-specific Cases of Traumatic Brain Injury in the United States (2018–2030)
Table 8: Gender-specific Incidence of Traumatic Brain Injury in the United States (2018–2030)
Table 9: Incidence of Traumatic Brain Injury by Age Group in the United States (2018–2030)
Table 10: Incident Cases of Traumatic Brain Injury in Germany (2018–2030)
Table 11: Severity-specific cases of Traumatic Brain Injury in Germany (2018–2030)
Table 12: Gender-specific Incidence of Traumatic Brain Injury in Germany (2018–2030)
Table 13: Incidence of Traumatic Brain Injury by Age group in Germany (2018–2030)
Table 14: Incident Cases of Traumatic Brain Injury in France (2018–2030)
Table 15: Severity-specific cases of Traumatic Brain Injury in France (2018–2030)
Table 16: Gender-specific Incidence of Traumatic Brain Injury in France (2018–2030)
Table 17: Incidence of Traumatic Brain Injury by Age Group in France (2018–2030)
Table 18: Incident Cases of Traumatic Brain Injury in Italy (2018–2030)
Table 19: Severity-specific of Traumatic Brain Injury in Italy (2018–2030)
Table 20: Gender-specific Incidence of Traumatic Brain Injury in Italy (2018–2030)
Table 21: Incidence of Traumatic Brain Injury by Age Group in Italy (2018–2030)
Table 22: Incident Cases of Traumatic Brain Injury in Spain (2018–2030)
Table 23: Severity-specific of Traumatic Brain Injury in Spain (2018–2030)
Table 24: Gender-specific Incidence of Traumatic Brain Injury in Spain (2018–2030)
Table 25: Incidence of Traumatic Brain Injury by Age Group in Spain (2018–2030)
Table 26: Incident Cases of Traumatic Brain Injury in the United Kingdom (2018–2030)
Table 27: Severity-specific cases of Traumatic Brain Injury in the United Kingdom (2018–2030)
Table 28: Gender-specific Incidence of Traumatic Brain Injury in the United Kingdom (2018–2030)
Table 29: Incidence of Traumatic Brain Injury by Age Group in the United Kingdom (2018–2030)
Table 30: Incident Cases of Traumatic Brain Injury in Japan (2018–2030)
Table 31: Severity-specific Cases of Traumatic Brain Injury in Japan (2018–2030)
Table 32: Gender-specific Incidence of Traumatic Brain Injury in Japan (2018–2030)
Table 33: Incidence of Traumatic Brain Injury by Age Group in Japan (2018–2030)
Table 34: Organizations contributing to Traumatic Brain Injury
Table 35: VAS203, Clinical Trial Description, 2021
Table 36: NeuroSTAT, Clinical Trial Description, 2021
Table 37: CEVA101, Clinical Trial Description, 2021
Table 38: 7 Major Market Size of Traumatic Brain Injury in USD Million (2018–2030)
Table 39: Seven Major Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)
Table 40: United States Market Size of Traumatic Brain Injury in USD Million (2018–2030)
Table 41: United States Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)
Table 42: Germany Market Size of Traumatic Brain Injury in USD Million (2018–2030)
Table 43: Germany Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)
Table 44: France Market Size of Traumatic Brain Injury in USD Million (2018–2030)
Table 45: France Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)
Table 46: Italy Market Size of Traumatic Brain Injury in USD Million (2018–2030)
Table 47: Italy Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)
Table 48: Spain Market Size of Traumatic Brain Injury in USD Million (2018–2030)
Table 49: Spain Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)
Table 50: United Kingdom Market Size of Traumatic Brain Injury in USD Million (2018–2030)
Table 51: United Kingdom Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)
Table 52: Japan Market Size of Traumatic Brain Injury in USD Million (2018–2030)
Table 53: Japan Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)
List of Figures:
Figure 1: Different phases of traumatic brain injury (TBI) pathophysiology and relative immune response
Figure 2: Schematic representation of pathophysiology of traumatic brain injury (TBI)
Figure 3: Multi-modality monitor in neurocritical care—illustrating cerebral microdialysis, intracranial pressure and brain tissue oxygenation monitoring
Figure 4: Decompressive Craniectomy
Figure 5: Incident Population of Traumatic Brain Injury in 7MM (2018–2030)
Figure 6: Incident Cases of Traumatic Brain Injury in the United States (2018–2030)
Figure 7: Severity-specific Cases of Traumatic Brain Injury in the United States (2018–2030)
Figure 8: Gender-specific Incidence of Traumatic Brain Injury in the United States (2018–2030)
Figure 9: Incidence of Traumatic Brain Injury by Age Group in the United States (2018–2030)
Figure 10: Incident Cases of Traumatic Brain Injury in Germany (2018–2030)
Figure 11: Severity-specific cases of Traumatic Brain Injury in Germany (2018–2030)
Figure 12: Gender-specific Incidence of Traumatic Brain Injury in Germany (2018–2030)
Figure 13: Incidence of Traumatic Brain Injury by Age group in Germany (2018–2030)
Figure 14: Incident Cases of Traumatic Brain Injury in France (2018–2030)
Figure 15: Severity-specific Cases of Traumatic Brain Injury in France (2018–2030)
Figure 16: Gender-specific Incidence of Traumatic Brain Injury in France (2018–2030)
Figure 17: Incidence of Traumatic Brain Injury by Age Group in France (2018–2030)
Figure 18: Incident Cases of Traumatic Brain Injury in Italy (2018–2030)
Figure 19: Severity-specific of Traumatic Brain Injury in Italy (2018–2030)
Figure 20: Gender-specific Incidence of Traumatic Brain Injury in Italy (2018–2030)
Figure 21: Incidence of Traumatic Brain Injury by Age Group in Italy (2018–2030)
Figure 22: Incident Cases of Traumatic Brain Injury in Spain (2018–2030)
Figure 23: Severity-Specific cases of Traumatic Brain Injury in Spain (2018–2030)
Figure 24: Gender-specific Incidence of Traumatic Brain Injury in Spain (2018–2030)
Figure 25: Incidence of Traumatic Brain Injury by Age Group in Spain (2018–2030)
Figure 26: Incident Cases of Traumatic Brain Injury in the United Kingdom (2018–2030)
Figure 27: Severity-specific Cases of Traumatic Brain Injury in the United Kingdom (2018–2030)
Figure 28: Gender-specific Incidence of Traumatic Brain Injury in the United Kingdom (2018–2030)
Figure 29: Incidence of Traumatic Brain Injury by Age Group in the United Kingdom (2018–2030)
Figure 30: Incident Cases of Traumatic Brain Injury in Japan (2018–2030)
Figure 31: Severity-specific of Traumatic Brain Injury in Japan (2018–2030)
Figure 32: Gender-specific Incidence of Traumatic Brain Injury in Japan (2018–2030)
Figure 33: Incidence of Traumatic Brain Injury by Age Group in Japan (2018–2030)
Figure 34: Seven Major Market Size of Traumatic Brain Injury in USD Million (2018–2030)
Figure 35: Seven Major Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)
Figure 36: Market Size of Traumatic Brain Injury in the United States, USD Million (2018–2030)
Figure 37: The United States Market Size of Traumatic Brain Injury by Therapies in USD Million
Figure 38: Market Size of Traumatic Brain Injury in Germany, USD Million (2018–2030)
Figure 39: The Germany Market Size of Traumatic Brain Injury by Therapies in USD Million
Figure 40: Market Size of Traumatic Brain Injury in France, USD Million (2018–2030)
Figure 41: The France Market Size of Traumatic Brain Injury by Therapies in USD Million
Figure 42: Market Size of Traumatic Brain Injury in Italy, USD Million (2018–2030)
Figure 43: The Italy Market Size of Traumatic Brain Injury by Therapies in USD Million
Figure 44: Market Size of Traumatic Brain Injury in Spain, USD Million (2018–2030)
Figure 45: The Spain Market Size of Traumatic Brain Injury by Therapies in USD Million
Figure 46: Market Size of Traumatic Brain Injury in the United Kingdom, USD Million (2018–2030)
Figure 47: The United Kingdom Market Size of Traumatic Brain Injury by Therapies in USD Million
Figure 48: Market Size of Traumatic Brain Injury in Japan, USD Million (2018–2030)
Figure 49: The Japan Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)
-Market-Infographic.jpg "Traumatic Brain Injury Market")